Form 4: IDEAYA Biosciences Director Malcolm Hampton Granted 20,000 Stock Options

IDEAYA Biosciences, Inc. Director Malcolm Garret Hampton was granted 20,000 stock options with an exercise price of $21.78, vesting over the next year.

Summary

• Malcolm Garret Hampton, a Director of IDEAYA Biosciences, Inc. (IDYA), was granted 20,000 stock options.
• The transaction date for this grant was June 24, 2025.
• The exercise price for these stock options is $21.78 per share.
• The options have an expiration date of June 24, 2035.
• The 20,000 shares subject to the option will vest 100% on the earlier of the first anniversary of the grant date or immediately prior to the Annual Meeting following the grant date, contingent on Mr. Hampton's continued service on the Board.

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it indicates continued alignment of a director's interests with shareholders through equity compensation, which is a standard and generally well-regarded practice.

Positives

• The grant of stock options to a director aligns their financial interests with those of the shareholders, incentivizing long-term company performance.
• The vesting schedule encourages the director's continued service and commitment to the company's strategic objectives.

Future Outlook

The stock options are set to vest 100% on the earlier of the first anniversary of the grant date (June 24, 2026) or immediately prior to the Annual Meeting following the grant date, subject to the director's continued service.

Industry Context

Stock option grants are a common form of executive and director compensation in the biotechnology industry, used to attract and retain talent and align their interests with long-term shareholder value creation. This grant is a routine compensation event for a director.

Related Party Transactions

• The grant of 20,000 stock options to Malcolm Garret Hampton, a Director of IDEAYA Biosciences, Inc., constitutes a related party transaction as it involves compensation to an insider.

Stakeholder Impact

• Shareholders: The grant aligns the director's financial incentives with shareholder interests, potentially leading to better long-term performance.
• Employees: No direct impact on general employees is indicated by this filing.

Next Steps

• The stock options will vest on the earlier of June 24, 2026, or immediately prior to the Annual Meeting following the grant date, provided the director remains on the Board.

Key Dates

Keywords

IDEAYA Biosciences, IDYA, Stock Options, Director Compensation, SEC Form 4, Insider Transaction, Equity Grant, Biotechnology